Kim Joon-Young, Chu Khoi, Kim Han-Jong, Seong Hyun-A, Park Ki-Cheol, Sanyal Sabyasachi, Takeda Jun, Ha Hyunjung, Shong Minho, Tsai Ming-Jer, Choi Hueng-Sik
Hormone Research Center, School of Biological Resources and Technology, Chonnam National University, Kwangju 500-757, Republic of Korea.
Mol Endocrinol. 2004 Apr;18(4):776-90. doi: 10.1210/me.2003-0311. Epub 2004 Jan 29.
Small heterodimer partner (SHP; NR0B2) is an atypical orphan nuclear receptor that lacks a conventional DNA binding domain (DBD) and represses the transcriptional activity of various nuclear receptors. In this study, we examined the novel cross talk between SHP and BETA2/NeuroD, a basic helix-loop-helix transcription factor. In vitro and in vivo protein interaction studies showed that SHP physically interacts with BETA2/NeuroD, but not its heterodimer partner E47. Moreover, confocal microscopic study and immunostaining results demonstrated that SHP colocalized with BETA2 in islets of mouse pancreas. SHP inhibited BETA2/NeuroD-dependent transactivation of an E-box reporter, whereas SHP was unable to repress the E47-mediated transactivation and the E-box mutant reporter activity. In addition, SHP repressed the BETA2-dependent activity of glucokinase and cyclin-dependent kinase inhibitor p21 gene promoters. Gel shift and in vitro protein competition assays indicated that SHP inhibits neither dimerization nor DNA binding of BETA2 and E47. Rather, SHP directly repressed BETA2 transcriptional activity and p300-enhanced BETA2/NeuroD transcriptional activity by inhibiting interaction between BETA2 and coactivator p300. We also showed that C-terminal repression domain within SHP is also required for BETA2 repression. However, inhibition of BETA2 activity was not observed by naturally occurring human SHP mutants that cannot interact with BETA2/NeuroD. Taken together, these results suggest that SHP acts as a novel corepressor for basic helix-loop-helix transcription factor BETA2/NeuroD by competing with coactivator p300 for binding to BETA2/NeuroD and by its direct transcriptional repression function.
小异二聚体伴侣蛋白(SHP;NR0B2)是一种非典型的孤儿核受体,它缺乏传统的DNA结合结构域(DBD),并能抑制多种核受体的转录活性。在本研究中,我们检测了SHP与碱性螺旋-环-螺旋转录因子BETA2/NeuroD之间新的相互作用。体外和体内蛋白质相互作用研究表明,SHP与BETA2/NeuroD存在物理相互作用,但与它的异二聚体伴侣E47没有相互作用。此外,共聚焦显微镜研究和免疫染色结果表明,SHP与小鼠胰腺胰岛中的BETA2共定位。SHP抑制E-box报告基因的BETA2/NeuroD依赖性反式激活,而SHP不能抑制E47介导的反式激活和E-box突变报告基因活性。此外,SHP抑制葡萄糖激酶和细胞周期蛋白依赖性激酶抑制剂p21基因启动子的BETA2依赖性活性。凝胶迁移和体外蛋白质竞争试验表明,SHP既不抑制BETA2和E47的二聚化,也不抑制它们与DNA的结合。相反,SHP通过抑制BETA2与共激活因子p300之间的相互作用,直接抑制BETA2的转录活性以及p300增强的BETA2/NeuroD转录活性。我们还表明,SHP的C末端抑制结构域对于抑制BETA2也是必需的。然而,不能与BETA2/NeuroD相互作用的天然人类SHP突变体未观察到对BETA2活性的抑制作用。综上所述,这些结果表明,SHP通过与共激活因子p300竞争结合BETA2/NeuroD并通过其直接的转录抑制功能,作为碱性螺旋-环-螺旋转录因子BETA2/NeuroD的新型共抑制因子发挥作用。